Search results for "therapy [Encephalitis]"

showing 10 items of 2838 documents

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

2018

Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-common hematologic malignancy. Despite advances in therapy, MM remains largely incurable. Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, which is highly expressed on myeloma cells, and the antibody is approved for the treatment of relapsed and/or refractory (RR) MM in combination with lenalidomide and dexamethasone. Elotuzumab can stimulate robust antibody-dependent cellular cytotoxicity (ADCC) through engaging with FcγRIIIA (CD16) on NK cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages. Interestingly, SLAMF7 is also expressed on cytolytic NK cells, which also expr…

0301 basic medicineReviewNK cellsLymphocyte ActivationDexamethasoneMice0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyElotuzumabLenalidomideMultiple myelomaAntibody-dependent cell-mediated cytotoxicityBortezomibSLAMF7ADCPPlasma cell neoplasmelotuzumab3. Good healthmultiple myelomaKiller Cells Naturalmedicine.anatomical_structureNK Cell Lectin-Like Receptor Subfamily K030220 oncology & carcinogenesisSLAMF7ADCCmedicine.druglcsh:Immunologic diseases. AllergyImmunologyPlasma CellsAntineoplastic AgentsmacrophageAntibodies Monoclonal HumanizedGPI-Linked Proteins03 medical and health sciencesPhagocytosisSignaling Lymphocytic Activation Molecule FamilymedicineBiomarkers TumorAnimalsHumansbusiness.industryNatural Cytotoxicity Triggering Receptor 1MacrophagesReceptors IgGNKG2Dmedicine.disease030104 developmental biologyCancer researchBone marrowbusinesslcsh:RC581-607Transcription FactorsFrontiers in Immunology
researchProduct

Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity

2017

Abstract Purpose: Neuroblastoma is a pediatric tumor of peripheral sympathoadrenal neuroblasts. The long-term event-free survival of children with high-risk neuroblastoma is still poor despite the improvements with current multimodality treatment protocols. Activated JAK/STAT3 pathway plays an important role in many human cancers, suggesting that targeting STAT3 is a promising strategy for treating high-risk neuroblastoma. Experimental Design: To evaluate the biologic consequences of specific targeting of STAT3 in neuroblastoma, we assessed the effect of tetracycline (Tet)-inducible STAT3 shRNA and the generation 2.5 antisense oligonucleotide AZD9150 which targets STAT3 in three representat…

0301 basic medicineSTAT3 Transcription FactorCancer Researchmedicine.disease_causeSmall hairpin RNA03 medical and health sciencesMiceNeuroblastoma0302 clinical medicineNeuroblastomaCell Line TumorOligonucleotidemedicineSTAT3CarcinogenesiCell ProliferationCisplatinAntineoplastic Combined Chemotherapy ProtocolbiologyCell growthAnimalCancerApoptosiOligonucleotides Antisensemedicine.diseaseXenograft Model Antitumor AssaysGene Expression Regulation Neoplastic030104 developmental biologyOncologyCell culture030220 oncology & carcinogenesisCancer researchbiology.proteinCisplatinCarcinogenesismedicine.drugHuman
researchProduct

Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal c…

2019

Abstract Human (gamma delta) γδ T cells are unconventional innate-like lymphocytes displaying a broad array of anti-tumor activities with promising perspectives in cancer immunotherapy. In this context, Vδ2pos T cells represent the preferential target of several immunotherapy protocols against solid tumors. However, the impact of both aging and chemotherapy (CHT) on Vδ2pos T cells is still unknown. The present study evaluates with multi-parametric flow cytometry the frequencies, terminal differentiation, senescence and effector-functions of peripheral blood and tumor infiltrating Vδ2pos T cells purified from liver metastases (CLM) of patients affected by colorectal cancer (CRC) compared to …

0301 basic medicineSenescenceCancer ResearchColorectal cancermedicine.medical_treatmentImmunologyShort ReportContext (language use)Antineoplastic AgentsCD16lcsh:RC254-282γδ T cellsFlow cytometryImmunophenotyping03 medical and health sciences0302 clinical medicineCancer immunotherapyT-Lymphocyte SubsetsCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsmedicineImmunology and AllergyChemotherapyHumansCellular SenescenceCancerPharmacologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCD28Receptors Antigen T-Cell gamma-deltaImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistry030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchMolecular MedicineImmune-senescence/AgingbusinessColorectal NeoplasmsBiomarkersJournal for Immunotherapy of Cancer
researchProduct

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placeb…

2018

Summary Background Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer. Methods We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 years) with platinum-resistant ovarian cancer previously treated with two or fewer chemotherapy lines for recurrent disease were stratified (first vs later relapse) in block sizes of four and randomly assigned (1:1) using a web-generated response system to topotec…

0301 basic medicineSorafenibAdultmedicine.medical_specialtyTime FactorsPerforation (oil well)Angiogenesis InhibitorsPlatinum CompoundsNeutropeniaPlaceboGastroenterologyDrug Administration Schedule03 medical and health sciences0302 clinical medicineMaintenance therapyDouble-Blind MethodInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalProtein Kinase InhibitorsAgedOvarian Neoplasmsbusiness.industryMiddle AgedSorafenibmedicine.diseaseProgression-Free Survival030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisDisease ProgressionTopotecanFemaleTopoisomerase I InhibitorsbusinessTopotecanmedicine.drugThe Lancet. Oncology
researchProduct

Training session intensity affects plasma redox status in amateur rhythmic gymnasts

2016

Purpose: The aim of this study was to examine systemic responses of oxidant/antioxidant status following 2 training sessions of different intensity in amateur rhythmic gymnasts. Methods: Before the experimental training, 10 female gymnasts performed a gradually increased exercise test to assess maximal heart rate, maximal oxygen consumption, and anaerobic threshold. They executed 2 intermittent training sessions separated by 48 h of recovery (48 h-post R): the first was performed at low-moderate intensity (LMI) and the second at high intensity (HI). Blood samples were collected immediately pre- and post-training and 48 h-post R. Hydroperoxide level (OxL) and total antioxidant capacity (TAC)…

0301 basic medicineTraining intensitymedicine.medical_specialtyeducationPhysical Therapy Sports Therapy and RehabilitationFree radicalsmedicine.disease_cause03 medical and health scienceslcsh:GV557-1198.9950302 clinical medicineRhythmInternal medicineHeart rateRegular PapermedicineOrthopedics and Sports MedicineExercise physiologylcsh:Sports medicineAntioxidant capacity; Exercise physiology; Free radicals; Oxidative stress; Reactive oxygen species; Rhythmic gymnastics; Training intensitylcsh:SportsSettore M-EDF/02 - Metodi E Didattiche Delle Attivita' Sportivebusiness.industryRhythmic gymnasticsVO2 max030229 sport sciencesExercise physiologyIntensity (physics)Antioxidant capacityAntioxidant capacity030104 developmental biologyEndocrinologyOxidative stressPhysical therapyAntioxidant capacity Exercise physiology Oxidative stress Free radicals Reactive oxygen species Training intensity Rhythmic gymnasticsbusinesslcsh:RC1200-1245Reactive oxygen speciesSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieAnaerobic exerciseOxidative stressJournal of Sport and Health Science
researchProduct

FROM EPIGENETICS TO ANTI-DOPING APPLICATION: A NEW TOOL OF DETECTION

2017

Eukaryotic genomes transcribe up to 90% of the genomic DNA but only 1–2% of these transcripts encode for proteins, whereas the vast majority are transcribed as non-coding RNAs (ncRNAs). They are divided into short ncRNA, particularly microRNA (miRNA) and small interference RNA (siRNA), and long ncRNAs. Noteworthy, they are unexpectedly stable since they are protected from degradation through different mechanisms: package in exosomes/microvesicles structures, in apoptotic bodies, in HDL lipoprotein, or by RNA binding proteins. For several years already, biomarkers have been used to detect biological disease; in the last years, a requirement appeared to find some of them to unearth the signs …

0301 basic medicinelcsh:SportspbiomarkersHDLChemistryDopingPublic Health Environmental and Occupational HealthBiophysicsPhysical Therapy Sports Therapy and RehabilitationNanotechnologydopingncRNA03 medical and health scienceslcsh:GV557-1198.995030104 developmental biologySettore BIO/10 - BiochimicaexosomeEpigeneticsmiRNA ABP Next generation sequencingncRNAHDL
researchProduct

Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment.

2020

The deregulation of a wide variety of protein kinases is associated with cancer cell initiation and tumor progression. Owing to their indispensable function in signaling pathways driving malignant cell features, protein kinases constitute major therapeutic targets in cancer. Over the past two decades, intense efforts in drug development have been dedicated to this field. The development of protein kinase inhibitors (PKIs) have been a real breakthrough in targeted cancer therapy. Despite obvious successes across patients with different types of cancer, the development of PKI resistance still prevails. Combination therapies are part of a comprehensive approach to address the problem of drug r…

0301 basic medicinemedicine.drug_class[SDV]Life Sciences [q-bio]Nitric OxideBiochemistry03 medical and health sciences0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNitric Oxide DonorsMolecular Targeted TherapyProtein kinase AProtein Kinase InhibitorsPharmacologybusiness.industryKinaseCancerProtein kinase inhibitormedicine.disease3. Good health030104 developmental biologyDrug developmentTumor progressionDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer cellCancer researchSignal transductionbusinessProtein KinasesSignal TransductionBiochemical pharmacology
researchProduct

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or me…

2020

Background Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in advanced colorectal or squamous cell head and neck cancers. With prospective serum and tumour biomarkers, we tested if P added to CF (CFP) improved OS in advanced ESCC. Patients and methods Eligible patients with confirmed ESCC that was not curatively resectable or did not qualify for definitive radiochemotherapy, were randomised 1 : 1 to receive CF [cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1–4] or CF plus P (9…

0301 basic medicinemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentPopulationMedizinGastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicinePanitumumabHumansProspective StudieseducationCisplatineducation.field_of_studyChemotherapybusiness.industryPanitumumabHazard ratioCommon Terminology Criteria for Adverse EventsHematologymedicine.diseaseErbB Receptors030104 developmental biologyTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisCarcinoma Squamous CellFluorouracilCisplatinbusinessProgressive diseasemedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

Trend of Drug Abuse in 2011– 2014 in Italy

2017

Doping, although was born as a medication and not with the purpose of enhancing performance, is a widespread practice in all sports, between amateur and gym-goers. The Italian sports federations were in second place worldwide for positive doping-test, after Russia. This review focuses on the analysis of data collected by Italian National Olympic Committee (CONI) in the 2012–2014 period, showing that the most commonly used substances were anabolic androgenic agents, glucocorticoids, diuretics and stimulants. Prevention in doping could be a key to limit the damage caused by this harmful practice both, for the physical health and the athlete’s moral integrity and anti-doping campai…

0301 basic medicinemedicine.medical_specialtyPhysiologydrug abuse physical health AAS glucocorticoids diuretics stimolantsPhysical Therapy Sports Therapy and Rehabilitationlcsh:Physiology03 medical and health scienceslcsh:GV557-1198.9950302 clinical medicineSettore BIO/10 - BiochimicamedicineOrthopedics and Sports Medicinelcsh:Sports medicinePsychiatrydrug abuselcsh:Sportsbiologyglucocorticoidslcsh:QP1-981AthletesMoral integrityPhysical healthmedicine.diseasebiology.organism_classificationAASdiureticsSubstance abusestimolantsPhysical limitations030104 developmental biologyTourism Leisure and Hospitality ManagementPsychologylcsh:RC1200-1245Amateurhuman activitiesphysical health030217 neurology & neurosurgeryCentral European Journal of Sport Sciences and Medicine
researchProduct